GILEAD SCIENCES (NASDAQ: GILD) Breakout Swing Trading Idea

8 months ago - Chartmill

TRADING IDEA (Momentum Swing Trading Breakout)

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read the full profile here.

STRATEGY

Breakout Swing Trading Idea

clean breakout during last trading session, wide range bullish bar closed near the high of day (+5.2%)
strongly increased buying volume
closing price above current daily resistance level
long term trend (weekly chart), price breakout above sideways trading channel

Last earnings: 2022-08-02

Next earnings: 2022-10-26

ACTUAL SETUP

Buy Stop | $66.36
Limit | $66.50
Stoploss | $63.44
Target | first and second target area on weekly chart

ADDITIONAL INFO/TIPS

Use our ChartMill Postion Sizing Tool to calculate the maximum number of shares you can buy, depending on your available capital!
Why using Stop Limit Orders?

Disclaimer: These trading ideas are merely to demonstrate what ChartMill is capable of and shows some typical results of a breakout filter. It is in no way actual financial advise to invest or trade in these stocks. The author has no pre-existing position in any of these stocks.

Back

GILD Links

GILD News

16 hours ago - The Motley FoolIs It Time to Buy These Ultra-Cheap Dividend Stocks?

These two biopharma stocks aren't exciting growth plays, but they are reliable income vehicles.

a day ago - The Motley FoolUp 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run

Viking Therapeutics stock might in the midst of a historic run.

3 days ago - Seeking AlphaNCNA stock crashes after setback for patent dispute (NASDAQ:NCNA)

NuCana (NCNA) lost ~36% on Monday after an EU panel invalidated its patent related to sofosbuvir, Gilead’s (GILD) FDA-approved Hepatitis C therapy. Read more here.

5 days ago - InvestorPlaceThe 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

7 days ago - Seeking AlphaGilead waives rights to acquire immune-oncology biotech Pionyr (NASDAQ:GILD)

California-based immune-oncology company Pionyr Immunotherapeutics announced Thursday that Gilead (GILD) has agreed to waive an exclusive option to acquire it. Read the full story here.

8 days ago - Gilead Sciences, Inc.Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

8 days ago - The Motley FoolA Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today

These stocks are all trading at less than 12 times their future profits.

8 days ago - TheNewswire.comWhat Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?

By Julian Richard, Benzinga

9 days ago - Seeking AlphaGilead's Kite lauds survival of Yescarta in B-cell lymphoma

Kite, a unit of Gilead Sciences (GILD), said that phase 3 data on its CAR-T therapy Yescarta demonstrated a significant improvement in overall survival compared to standard treatment...

9 days ago - Gilead Sciences, Inc.Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

10 days ago - Seeking AlphaGamida Cell names Shawn Cline Tomasello chairwoman (NASDAQ:GMDA)

Gamida Cell (GMDA) on Monday announced the resignation of chairman Robert Blum and the appointment of Shawn Cline Tomasello as chairwoman, effective immediately.

10 days ago - Seeking AlphaGilead licenses protein degrader from Nurix Therapeutics (NASDAQ:GILD)

In line with a 2019 agreement, Gilead (GILD) has exercised its option to exclusively license an investigational protein degrader from Nurix Therapeutics (NRIX). Read the full story here.